Data from multiple sources - Curated by Toby Galbraith - Last updated 11 April 2017

Focus on Other Skin Disorders

Even mild skin disease can cause significant distress for patients, due to associated visibility and stigma, and this is of particular relevance for conditions which affect the face and hands. In this broad topic we cover conditions ranging in severity from life-threatening and highly disfiguring such as harlequin ichthyosis, to conditions as benign as freckles.

Read more on Other skin disorders

 

Latest news articles

Added 10 days ago Drug news

Phase III study of Nucala (mepolizumab) in Eosinophilic Granulomatosis with Polyangiitis published in NEJM- GlaxoSmithKline

GlaxoSmithKline has announced publication in the New England Journal of Medicine, of a randomised, double-blind, placebo controlled study investigating the...

Added 1 month ago Drug news

Phase IV study results for Restylane dermal fillers indicate benefits in facial expressions- Galderma

Galderma announced the results from two Phase IV clinical studies of its most recent additions to the Restylane family of...

View all news articles

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria (CSU)

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more

Visit Type 2 Diabetes

Guidelines

Canadian Guidelines for the Management of Plaque Psoriasis 2009

Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases. 

Added 3 months ago

Adalimumab for treating moderate to severe hidradenitis suppurativa

Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

Added 3 months ago

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

In recognition of the impact of psoriasis on patients the World Health Assembly (WHA) in May 2014 supported including psoriasis into the group of non-communicable diseases.

Added 3 months ago

View all guidelines

Journal articles

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.

Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment...

Added 1 month ago

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis,

The proinflammatory cytokine interleukin (IL)-17A plays a pivotal role in psoriasis pathogenesis. Secukinumab, a fully human monoclonal antibody (mAb) that selectively targets IL-17A, has...

Added 1 month ago

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).

Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate-to-severe psoriasis...

Added 1 month ago

View all journal articles

Clinical trials

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 3 months ago

Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting - HARMONY Study

This study will assess the effects of adalimumab treatment in moderate to severe Hidradenitis Suppurativa (HS) patients in the real world setting.

Added 3 months ago

Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) (SHARPS)

The objective of this study is to assess the safety and efficacy of adalimumab prior to surgery in subjects with moderate to severe Hidradenitis Suppurativa (HS) who are surgical candidates.

Added 3 months ago

View all clinical trials
Liam Farrell

Dr Liam Farrell is from Rostrevor in Northern Ireland. He was a family doctor in Crossmaglen, Northern Ireland and a tutor in palliative care. An award-winning satirical columnist and broadcaster, his current columns include the British Medical Journal and GP. He is a member of the ... Read more

Bad smells are good

Delicacy is not a virtue in this job.

CME

Dermatological emergencies in children

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0

Emergencies in dermatology

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0

Management of hidradenitis suppurativa

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90
View all CME